Crossmark

394 Interleukin-8–neutralizing monoclonal antibody BMS-986253 plus nivolumab (NIVO) in biomarker-enriched, primarily anti–PD-(L)1–experienced patients with advanced cancer: initial phase 1 results

Crossref DOI link: https://doi.org/10.1136/jitc-2020-SITC2020.0394

Published Online: 2020-12-10

Published Print: 2020-11

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Davar, Diwakar

Simonelli, Matteo

Gutierrez, Martin

Calvo, Emiliano

Melear, Jason

Piha-Paul, Sarina

Richards, Donald

Dallos, Matthew

Parameswaran, Janaki

Kumar, Vinit

Zhao, Xiaochen

Dutta, Santanu

Melero, Ignacio
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct03400332 at ClinicalTrials.gov

Documents that mention this clinical trial

394 Interleukin-8–neutralizing monoclonal antibody BMS-986253 plus nivolumab (NIVO) in biomarker-enriched, primarily anti–PD-(L)1–experienced patients with advanced cancer: initial phase 1 results
https://doi.org/10.1136/jitc-2020-sitc2020.0394
License Information

License valid from 2020-12-09

Document is current

Any future updates will be listed below